Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A2 | O15244 | 1/20 | 0.39 |
| ▸ | SLC47A1 | Q96FL8 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | DPP4 | P27487 | 6/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22551596 | 0.90 | SLC22A2 (0.37) | SLC22A2SLC47A1MAPTALDH1A1NPC1 | |
| SCHEMBL23781793 | 0.81 | SLC22A2 (0.42) | SLC22A2SLC47A1MAPTALDH1A1NPC1 | |
| SCHEMBL10231170 | 0.79 | EPHX2 (0.36) | SLC22A2SLC47A1MAPTALDH1A1NPC1 | |
| SCHEMBL22551574 | 0.78 | GRIN1 (0.36) | EPHX2MEN1CYP2D6CYP2C19KMT2A | |
| SCHEMBL10231177 | 0.76 | ALDH1A1 (0.36) | MAPTALDH1A1EPHX2ALOX15 | |
| SCHEMBL2536293 | 0.75 | SLC22A2 (0.46) | SLC22A2SLC47A1MAPTALDH1A1NPC1 | |
| SCHEMBL28310832 | 0.73 | KDM4E (0.42) | SLC22A2SLC47A1MAPTALDH1A1NPC1 | |
| SCHEMBL660251 | 0.71 | SLC22A2 (0.52) | SLC22A2SLC47A1MAPTALDH1A1NPC1 | |
| SCHEMBL353492 | 0.71 | SLC22A2 (0.46) | SLC22A2SLC47A1MAPTALDH1A1NPC1 | |
| SCHEMBL16219773 | 0.70 | GRIN2D (0.37) | MAPTALDH1A1EPHX2MEN1CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110396165-B | Ionically hydrophilicized polyisocyanates and antioxidants | 科思创德国股份有限公司 | 2022-12-06 | — | — | CN | disclosed |
| CN-112041369-B | Ionically hydrophilicized polyisocyanates, water content | 科思创知识产权两合公司 | 2022-11-29 | — | — | CN | disclosed |
| CN-115066445-A | Polyisocyanate formulations | 科思创德国股份有限公司 | 2022-09-16 | — | — | CN | disclosed |
| CN-113651944-B | Ionically hydrophilicized polyisocyanates having improved drying properties | 科思创知识产权两合公司 | 2022-07-15 | — | — | CN | disclosed |
| CN-112062935-B | Preparation method and application of odorless water-dispersible polyisocyanate | 广东也乐新材料制造有限公司 | 2022-02-11 | — | — | CN | disclosed |
| CN-112566957-B | Ionically hydrophilicized polyisocyanates having improved drying properties | 科思创知识产权两合公司 | 2021-12-10 | — | — | CN | disclosed |
| CN-113651944-A | Ionically hydrophilicized polyisocyanates having improved drying properties | 科思创知识产权两合公司 | 2021-11-16 | — | — | CN | disclosed |
| EP-3875513-A1 | IONICALLY HYDROPHILIZED POLYISOCYANATES AND RADICAL SCAVENGER AND/OR PEROXIDE DECOMPOSITION AGENT | Covestro Intellectual Property GmbH & Co. KG (DE) | 2021-09-08 | — | — | EP | disclosed |
| CN-112566957-A | Ionically hydrophilicized polyisocyanates having improved drying properties | 科思创知识产权两合公司 | 2021-03-26 | — | — | CN | disclosed |
| CN-112062935-A | Preparation method and application of odorless water-dispersible polyisocyanate | 广东也乐新材料制造有限公司 | 2020-12-11 | — | — | CN | disclosed |
| US-20120015911-A1 | METHOD AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | BELLUS HEALTH INC. (CA) | 2012-01-19 | — | — | US | disclosed |
| US-20120015911-A1 | METHOD AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | BELLUS HEALTH INC. (CA) | 2012-01-19 | — | — | US | disclosed |
| US-20120015911-A1 | METHOD AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | BELLUS HEALTH INC. (CA) | 2012-01-19 | — | — | US | disclosed |
| US-8044100-B2 | Methods and compositions for treating amyloid-related diseases | BELLUS HEALTH INC. (CA) | 2011-10-25 | — | — | US | disclosed |
| US-8044100-B2 | Methods and compositions for treating amyloid-related diseases | BELLUS HEALTH INC. (CA) | 2011-10-25 | — | — | US | disclosed |
| US-8044100-B2 | Methods and compositions for treating amyloid-related diseases | BELLUS HEALTH INC. (CA) | 2011-10-25 | — | — | US | disclosed |
| CN-101128421-A | Methods and compositions for treating amyloid-related diseases | NEUROCHEM INTERNAT LTD (CH) | 2008-02-20 | — | — | CN | disclosed |
| EP-1836161-A2 | METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | Neurochem (International) Limited (CH) | 2007-09-26 | — | — | EP | disclosed |
| US-20060223855-A1 | reduces or inhibits amyloid fibril formation, organ specific dysfunction (e.g., neurodegeneration), or cellular toxicity | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2006-10-05 | — | — | US | disclosed |
| WO-2006085149-A2 | METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2006-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060223855-A1 | reduces or inhibits amyloid fibril formation, organ specific dysfunction (e.g., neurodegeneration), or cellular toxicity | APP, IAPP, BACE1 | SLC22A2 2158/4885SLC47A1 125/4885MAPT 12/4885 |
| US-20120015911-A1 | METHOD AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | APP, PSEN1, PSEN2 | SLC22A2 1455/4885SLC47A1 487/4885MAPT 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.